Literature DB >> 3926301

Interactions of mitomycin C with mammalian DNA detected by alkaline elution.

R T Dorr, G T Bowden, D S Alberts, J D Liddil.   

Abstract

The antitumor antibiotic mitomycin C (MMC) was studied in vitro using L1210 leukemia and 8226 human myeloma cells. Cytotoxicity was evaluated by colony formation in soft agar, and DNA damage was analyzed using alkaline elution filter assays. The purposes of these studies were: (a) to characterize the time course of MMC-DNA damage; (b) to characterize the type of DNA damage [DNA-DNA interstrand cross-links (ISC), DNA-protein cross-links (DPC), single and double strand breaks (SSBs, DSBs)]; and (c) to correlate this damage with cytotoxicity in vitro. Colony-forming assays showed the D0 value for 1 h MMC to be 15.0 microM for L1210 cells and 17 microM for 8226 cells. Alkaline elution studies showed that dose-dependent ISCs and DPCs formed rapidly following MMC exposure. Removal of cross-links was delayed, with only 50% repaired 32 h after exposure. There was a good correlation between ISCs and cytotoxicity in dose-response studies in each cell line. ISCs appeared to comprise most of the MMC-DNA lesions in both cell lines. No DNA SSBs or DSBs were observed following MMC exposure. Nuclei isolated from both cell lines and exposed to MMC produced less MMC alkylation than whole cells but, again, no strand breaks were evident. These results demonstrate that MMC is principally an alkylating agent when used at pharmacological (cytotoxic) concentrations in vitro. The lack of evidence for DNA strand breaks discounts a significant role for putative quinone-generated oxygen free radicals in the production of MMC cytotoxicity.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3926301

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  13 in total

1.  Mapping DNA adducts of mitomycin C and decarbamoyl mitomycin C in cell lines using liquid chromatography/ electrospray tandem mass spectrometry.

Authors:  Manuel M Paz; Sweta Ladwa; Elise Champeil; Yanfeng Liu; Sara Rockwell; Ernest K Boamah; Jill Bargonetti; John Callahan; John Roach; Maria Tomasz
Journal:  Chem Res Toxicol       Date:  2008-12       Impact factor: 3.739

2.  Effect of varying the exposure and 3H-thymidine labeling period upon the outcome of the primary hepatocyte DNA repair assay.

Authors:  T R Barfknecht; D J Mecca; R W Naismith
Journal:  Cell Biol Toxicol       Date:  1988-06       Impact factor: 6.691

Review 3.  Role of DNA repair in the mechanisms of cell resistance to alkylating agents and cisplatin.

Authors:  P Calsou; B Salles
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

4.  Mitigating effect of Indian propolis against mitomycin C induced bone marrow toxicity.

Authors:  Sandhya Kumari; Prashantha Naik; B L Vishma; Sujith Raj Salian; Raviraj Anand Devkar; Saleemulla Khan; Srinivas Mutalik; Guruprasad Kalthur; Satish Kumar Adiga
Journal:  Cytotechnology       Date:  2015-11-21       Impact factor: 2.058

Review 5.  Are reduced quinones necessarily involved in the antitumour activity of quinone drugs?

Authors:  J Butler; B M Hoey
Journal:  Br J Cancer Suppl       Date:  1987-06

6.  Differential toxicity of mitomycin C and porfiromycin to aerobic and hypoxic Chinese hamster ovary cells overexpressing human NADPH:cytochrome c (P-450) reductase.

Authors:  M F Belcourt; W F Hodnick; S Rockwell; A C Sartorelli
Journal:  Proc Natl Acad Sci U S A       Date:  1996-01-09       Impact factor: 11.205

7.  Variations on the standard protocol design of the hepatocyte DNA repair assay.

Authors:  T R Barfknecht; R W Naismith; D J Kornbrust
Journal:  Cell Biol Toxicol       Date:  1987-06       Impact factor: 6.691

8.  Modification of cellular DNA by synthetic aziridinomitosenes.

Authors:  Chris M Mallory; Ryan P Carfi; SangPhil Moon; Kenneth A Cornell; Don L Warner
Journal:  Bioorg Med Chem       Date:  2015-10-21       Impact factor: 3.641

9.  Enhancement of antitumor activity of mitomycin C in vitro and in vivo by UCN-01, a selective inhibitor of protein kinase C.

Authors:  S Akinaga; K Nomura; K Gomi; M Okabe
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

10.  Effectiveness of isolated liver perfusion with mitomycin C in the treatment of liver tumours of rat colorectal cancer.

Authors:  A Marinelli; F R Dijkstra; J H van Dierendonck; P J Kuppen; C J Cornelisse; C J van de Velde
Journal:  Br J Cancer       Date:  1991-07       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.